Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Been looking at dividend stocks lately and honestly, there's something to be said for companies that actually stick to their payouts no matter what the market throws at them.
Johnson & Johnson is one of those rare picks. Yeah, it's not the sexiest company to talk about - pharma and medtech isn't exactly thrilling - but that's kind of the point. The business just works. They've got this massive portfolio of approved drugs, medical devices across different therapeutic areas, and revenue keeps growing even when they're dealing with patent cliffs and drug price negotiations. They're actually expecting sales to hit $100 billion this year for the first time. The balance sheet is solid too - literally has a better credit rating than the U.S. government.
What really caught my attention though is their innovation pipeline. They're waiting on approval for Ottava, a robotic-assisted surgery system that could be a serious growth driver. Plus they've got dozens of clinical trials running that'll help them keep the portfolio fresh. And here's the kicker - they're a Dividend King. That means 50+ years of consecutive annual dividend increases. That's the kind of track record dividend hunters actually look for.
Then there's Zoetis. Animal health play. They had a rough year with some of their OA pain treatments (Librela and Solensia) facing safety concerns, but they've already got replacements ready - Lenivia and Portela. These new ones are longer-acting too, so they'd probably take market share anyway. The company's been solid at launching better products consistently. Apoquel, their allergic itch treatment for dogs, was a breakthrough over a decade ago and there's still huge untreated market potential globally.
The trend working in Zoetis's favor is pretty interesting actually - younger generations are choosing pets over kids. That's a real tailwind for the animal health space. And their dividend? Up 458% over the past decade. That's the kind of growth you want to see from a dividend stock.
Both are solid picks if you're looking for companies that actually increase payouts even when things get messy. The kind of weekly dividend consistency people talk about comes from companies with this kind of staying power. Worth keeping on your radar if you're building an income portfolio.